Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0853 Drug Interaction Study with Midazolam, Rosuvastatin, Simvastatin, and Itraconazole
NCT03174041Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fenebrutinib in multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and 1 more (4 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Concentration at Day 12 and Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration at Day 12. Started Apr 2017; status: completed.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03174041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174041.